Windward Bio is a clinical-stage drug development company based in Switzerland, focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is developing a novel long-acting monoclonal antibody targeting the TSLP ligand and is building a discovery pipeline of long-acting bispecifics to address high unmet medical needs and reduce treatment burdens globally.
